Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleProceedings of the 4th International Symposium on Vitamin D and Analogs in Cancer Prevention and Therapy, May 20-21, 2011, Homburg/Saar, Germany

Signature of VDR miRNAs and Epigenetic Modulation of Vitamin D Signaling in Melanoma Cell Lines

SALMA ESSA, SANDRA REICHRATH, ULRICH MAHLKNECHT, MATHIAS MONTENARH, THOMAS VOGT and JÖRG REICHRATH
Anticancer Research January 2012, 32 (1) 383-389;
SALMA ESSA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ssessa77@hotmail.com
SANDRA REICHRATH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ULRICH MAHLKNECHT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MATHIAS MONTENARH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
THOMAS VOGT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JÖRG REICHRATH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background: Melanoma cells express the nuclear vitamin D receptor (VDR), indicating that malignant melanoma represents a promising target for treatment with 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) or its analogs. We previously showed that some melanoma cell lines are resistant to the antiproliferative effects of 1,25(OH)2D3 and that 1,25(OH)2D3-sensitivity can, at least in part, be restored by co-treatment with the histone deacetylase inhibitor (HDACI) Trichostatin A (TSA) or with the DNA methyltransferase inhibitor (DNMTI), 5-azacytidine (5-Aza). This study aimed at gaining further insights into the molecular mechanisms that underlie the epigenetic modulation of 1,25(OH)2D3-sensitivity in melanoma cells. Materials and Methods: The expression of VDR mRNA, protein and two candidates of VDR microRNAs (miR-125b, miR-27b) were compared in 1,25(OH)2D3-responsive (MeWo, SK-Mel28) and -resistant (SK-Mel5, IGR) melanoma cell lines and in normal human melanocytes (NHM) using real time PCR and western blot analysis. Additionally, the effect of 1,25(OH)2D3, epigenetic modulating drugs (TSA, 5-Aza) and miR-125b antisense on the expression of VDR messenger RNA (mRNA)/protein, miR-125b and miR-27b was investigated. Results: Treatment with 1,25(OH)2D3 and/or epigenetic drugs (5-Aza, TSA) modulated the VDR mRNA expression in the 1,25(OH)2D3-responsive and - resistant melanoma cell lines and in the NHM. Treatment with 5-Aza, but not with TSA, reduced the expression of miR-125b in the 1,25(OH)2D3-responsive and -resistant melanoma cell lines and in the NHM. Treatment with 1,25(OH)2D3 and/or epigenetic drugs (5-Aza, TSA) reduced the miR-27b expression in three out of four melanoma cell lines. Moreover, no difference was observed in VDR protein expression in the 1,25(OH)2D3-responsive as compared to the 1,25(OH)2D3-resistant melanoma cell lines. Transfection with miR-125b antisense did not affect the VDR mRNA/protein expression in the IGR cells. Conclusion: Responsiveness to 1,25(OH)2D3 corresponds to the expression level of VDR mRNA which in turn might be regulated by VDR microRNAs or epigenetic modulating drugs.

  • Vitamin D receptor
  • malignant melanoma
  • TSA
  • 5-Aza
  • microRNA antisense
  • MeWo
  • SK-Mel28
  • SK-Mel5
  • IGR
  • epigenetic silencing
  • miR-125b
  • miR-27b

5-Aza, 5-azacytidine; DNMTI, DNA methyltransferase inhibitor; HDACI, histone deacetylase inhibitor; mRNA, messenger ribonucleic acid; miR, microRNA; NHM, normal human melanocytes; TSA, Trichostatin; VDR, vitamin D receptor.

At present, there are no effective treatments for metastasized malignant melanoma available that can significantly reduce its mortality rates, underlining the need for the development of new therapeutic approaches for such an aggressive form of cancer (1). It is well established that the biologically active vitamin D metabolite 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) acts as a potent regulator of cellular processes such as normal cell growth, differentiation, and apoptosis of a wide variety of cancer cells including melanoma cells (2). Several molecular studies reported 1,25(OH)2D3 -insensitivity in melanoma, breast, or prostate cancer cells (3;4). Until today, the molecular mechanisms behind this resistance are unclear. 1,25(OH)2D3 exerts its effects at least in part by binding with high affinity to a member of the nuclear receptor superfamily (the vitamin D receptor (VDR)).

Recently, epigenetic events have attracted more and more attention due to their involvement in cancer development and the potential of therapeutic intervention (5, 6). In our previous study, 1,25(OH)2D3-insensitivity in melanoma cell lines was overcome using epigenetic modulating drugs (3, 5). Additive effects of 30-40% growth inhibition after treatment with 1,25(OH)2D3 in combination with histone deacetylase inhibitor (HDACI), trichostatin (TSA), or DNA methyltransferaseinhibitor (DNMTI), 5-azacytidine (5-Aza) were also observed. Additionally, we previously showed a correlation between the VDR messenger RNA (mRNA) expression level and 1,25(OH)2D3-responsiveness.

In the present study 1,25(OH)2D3-responsiveness analyzed the correlation of VDR protein level and in addition, the effect of 1,25(OH)2D3 alone and/or in combination with TSA or 5-Aza on the expression level of VDR mRNA was invistigated. In the last few years, increasing evidence has been found that a large number of microRNA (miR) genes are subjected to epigenetic alterations, resulting in aberrant expression patterns upon the incidence of cancer (7). For this reason, the impact of treatment with 1,25(OH)2D3 alone and/or in combination with TSA or 5-Aza on the expression level of two VDR miR candidates (miR-125b and miR-27b) in 1,25(OH)2D3-responsive cells (MeWo and SK-Mel28) and 1,25(OH)2D3-resistant cells (SK-Mel5 and IGR) was analyzed. It was previously shown by another group that miR-27b interacted with VDR 3’UTR, identifying this miRNA as a potential VDR miRNA (8). miR-125b posttranscriptionally negatively regulates human VDR in breast cancer cells (9). In order to modulate VDR expression miR-125b antisense and the effect on transcriptional and translational VDR regulation in melanoma cell lines, was investigated.

Materials and Methods

Cell culture. The human melanoma cell lines MeWo, SK-Mel-28, SK-Mel-5 and IGR (Department of Dermatology, Saarland University Hospital) were cultivated in RPMI media supplemented with 10% foetal calf serum (FCS) and 1% L-glutamine. Primary normal human melanocytes (NHM) were isolated from human foreskin and cultivated in serum free melanocyte growth medium M2 (Ready-to-use, PromoCell®, Heidelberg, Germany), after the addition of Melanocyte Growth Medium M2 supplement mix (C-39420) (PromoCell®). 1,25(OH)2D3 and TSA (Sigma-Aldrich, Taufkirchen, Germany) were dissolved in ethanol as stock solutions (4 mM and 1 mg/ml, respectively) and stored in the dark at −20°C, 5-Aza (Sigma-Aldrich) was dissolved in PBS (10 mM). Media containing varying concentrations of 1,25(OH)2D3, TSA or 5-Aza and their combinations were added to cultured cells 24 h after seeding the cells (to ensure semi confluent density) in 10 cm tissue culture dishes (Greiner Bio-One GmbH, Frickenhausen, Germany).

Apoptosis detection. Detection of apoptosis by FACS is based on the observation that soon after initiating apoptosis, most cell types translocate the membrane phospholipid phosphatidylserine (PS) from the inner face of the plasma membrane to the cell surface. Once on the cell surface, PS can be easily detected by staining with a fluorescent conjugate of Annexin V, a protein which has a strong natural affinity for PS. FACS was performed using an Annexin V-PE Apoptosis Detection Kit (Biovision Research Products, Mountain View, USA) according to the manufacturer's protocol. Cells were resuspended in 500 μl of 1× annexin V-PE binding buffer followed by adding 3 μl of Annexin V-PE and incubated at room temperature for 5 min in the dark. Apoptosis was measured using FACscan flow cytometry. Apoptosis detection by FACS is based on the observation that soon after initiating apoptosis, most cell types translocate the phospholipid phosphatidylserine (PS) from the inner face of the plasma membrane to the cell surface. Once at the cell surface, PS can be easily detected by staining with a fluorescent conjugate of annexin V, a protein which has a strong natural affinity for PS.

mRNA and miRNA isolation. RNA isolation was performed using a RNeasy Kit (Qiagen) according to the manufacturer's manual. The miRs were isolated using a miRNeasy Kit (Qiagen). The expression of VDR mRNA, miR-27b, and miR-125b were analyzed in the melanoma cell lines using real time PCR (LightCycler, Roche Diagnostic, Mannheim, Germany), 50 cycles.

Real time-PCR. RT reaction mixture was used as the template for real-time PCR, containing 2 μl of 10× VDR primers or 10× hypoxanthine guanine phosphoribosyl transferase (HPRT) primer (house keeping gene) purchased from Qiagen, (Catalogue number QT01010170, QT00059066). A final concentration of 1 mM MgCl2 in the miR-125b or miR-27b RT reaction mixture was used as the template for real-time PCR, containing 2 μl of 10× miR-125b primer or 10x miR-27b primer and 10× RNU6B (RNU6B is a widely used endogenous reference RNA in many miRNA quantification studies because of its small size 45 nt), purchased from Qiagen (miScript Primer Assay and miScript universal primer).

miR-125b antisense. The IGR melanoma cells were seeded (to ensure semi confluent density) in 6 well plate in 2 ml RPMI media supplemented with 10%, 1% L-glutamine and 1% penicillin/streptomycin. The medium was changed after 24 h and transfection of the cells with miScript miRNA-125b inhibitor, miScript inhibitor (negative control) or HiPerFect transfection reagent (mock control), (Qiagen) was carried out according to the manufacturer's manuals. The miRNAs were isolated after 24 h from the media control, mock control, negative control, and miR-125b antisense wells.

Western blotting. The nuclear proteins were extracted using a NEPER® Nuclear and Cytoplasmic Extraction Reagents Kit (ThermoFisher Scientific) and Complete Protease Inhibitor Cocktail (Roche Diagnostics, Mannheim, Germany) according to the manufacturer's manuals. Briefly the cell membrane was disrupted and the cytoplasmic contents were released then after recovering the intact nuclei from the cytoplasmic extract by centrifugation, the nuclei were lysed to yield the nuclear extract. The protein concentration was determined using a Bradford (Bio-Rad, Protein Assay, Bio-Rad Laboratories GmbH, Muenchen) protein assay and finally 40 μg of nuclear protein from each sample were used. Based on the finding that VDR protein level was relatively high in MCF7 breast cancer cell lines (10), we used this cell line as VDR protein positive control. After electrophoresis in 12.5% SDS-polyacrylamide gels, separated proteins were electrophoretically transferred to a PVDF membrane. Non-specific sites were blocked by 5% non-fat dry milk in PBS for 1 h at room temperature. The membrane was incubated with the primary antibody (VDR polyclonal (C-20): sc-1008 or VDR monoclonal (D-6): sc-13133, Santa Cruz Biotechnology, Santa Cruz, CA, USA) overnight at 4°C or with the primary antibody nucleolin (11) as a loading control for 1 h at room temperature in PBS containing 1% non-fat dry milk, washed three times with PBS for 10 min and incubated 1 h with the respective secondary antibody in PBS containing 1% non-fat dry milk. After washing, bands were visualized by chemiluminescence. The intensity of VDR band was analyzed using Bio-Rad Quantity One® 1-D analysis software in relation to the loading control gene band (nucleolin) in three independent experiments.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Baseline expression level of VDR mRNA, miR-125b and miR-27b.

Results

Basal expression of VDR mRNA, miR-125b and miR-27b. Real time RT-PCR analysis demonstrated an inversely correlated expression pattern of VDR mRNA and miR-125b in the 1,25(OH)2D3-responsive (MeWo, SK-Mel28) as compared to the 1,25(OH)2D3-resistant (IGR, SK-Mel5) melanoma cells as reported previously (3) (Figure 1). The expression level of miR-27b was relatively low in the MeWo (1,25(OH)2D3-responsive) cells as compared to the IGR (1,25(OH)2D3-resistant) cells, while the SK-Mel28 (1,25(OH)2D3-responsive) cells and SK-Mel5 (1,25(OH)2D3-resistant) cells showed similar expression levels (Figure 1). In the NHM VDR mRNA expression level was comparable to that of the 1,25(OH)2D3-responsive melanoma cell lines (MeWo, SK-Mel28), while, the VDR mRNA expression level in the 1,25(OH)2D3-resistant melanoma cell lines (SK-Mel5, IGR) was much lower.

Interestingly, the miR-125b in particular and also the miR-27b expression levels were higher both in the NHM and in the 1,25(OH)2D3-resistant melanoma cell lines as compared to the 1,25(OH)2D3-responsive cell lines (Figure 1). The 1,25(OH)2D3-responsive cell lines were characterized by a relatively high expression of VDR mRNA and a low-expression of miR-125 and miR-27b (in MeWo cells only for miR-27b).

Expression of VDR mRNA, miR-125b, and miR-27b after treatment with 1,25(OH)2D3, 5-Aza, and/or TSA. As 1,25(OH)2D3 and epigenetic modulating drugs such as TSA and 5-Aza are cytotoxic at high concentration, it was important to avoid toxic effects in our study. Using the apoptosis detection analysis kit the concentrations in which apoptotic and dead cells did not exceed 10-20% were determined. Concentrations of 10−8 M for 1,25(OH)2D3, 10 μM for 5-Aza, and 15 ng/ml for TSA showed no cytotoxic effect on melanoma cell lines (data not shown) and were therefore chosen for the experiments. The treatment with 1,25(OH)2D3 alone or in combination with the epigenetic drugs increased the expression of VDR mRNA in the NHM (Figure 2a). Moreover, treatment with 1,25(OH)2D3 alone increased VDR mRNA in two out of four melanoma cell lines, but this effect was statistically insignificant (p>0.05). 5-Aza alone increased the VDR mRNA in the 1,25(OH)2D3-resistant melanoma cells (Figure 2a), but this effect was statistically in-significant. The increase in VDR mRNA expression was more pronounced in three out of the four melanoma cell lines after treatment with 1,25(OH)2D3 in combination with 5-Aza, while treatment with TSA alone or in combination with 1,25(OH)2D3 resulted in a reduced level of VDR mRNA in three out of the four melanoma cell lines. In the other 1,25(OH)2D3-resistant cell line (IGR), treatment with TSA alone or in combination with 1,25(OH)2D3 increased VDR mRNA level (Figure 2a). The treatment with 1,25(OH)2D3 alone decreased the miR-125b expression in 3 out of the 4 melanoma cell lines. The treatment with 5-Aza alone or in combination with 1,25(OH)2D3 also significantly decreased the miR-125b expression in all the melanoma cell lines also reduced the level in the NHM. In contrast, treatment with TSA alone or in combination with 1,25(OH)2D3 did not significantly affect the expression miR-125b (except in MeWo cells) (Figure 2b). This effect of TSA alone or combined with 1,25(OH)2D3 (decrease the VDR mRNA and did not affect the miR-125b) on 1,25(OH)2D3-responsive cell lines (Figure 2a, 2b) might be, at least in part, the reason for losing the additive antiproliferative effect of these two compounds in 1,25(OH)2D3-responsive cell lines that we reported previously (3).

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

a: Effect of treatment with 1,25(OH)2D3 and/or epigenetic drugs (5-Aza, TSA) on VDR mRNA expression. NHM and melanoma cells were treated with 1,25(OH)2D3 (10−8 M), 5-Aza (10 μM) and TSA (15 ng/ml) alone or in combination with 1,25(OH)2D3. RT-PCR of VDR mRNA levels was compared to vehicle-treated controls. After 24 h treatment, mRNA was isolated and experiments were performed in duplicate and repeated twice. Error bars represent the SD, *p≤0.05. b: Effect of treatment with 1,25(OH)2D3 and/or epigenetic drugs (5-Aza, TSA) on m-R-125b expression. NHM and melanoma cells were treated with 1,25(OH)2D3 (10−8 M), 5-Aza (10 μM), and TSA (15 ng/ml) alone or in combination with 1,25(OH)2D3. RT-PCR quantified miR-125b and compared to vehicle-treated control, after 24 h of treatment. Experiments were performed in duplicate and repeated at least twice. Error bars represent the SD, *p≤0.05. c: Effect of treatment with 1,25(OH)2D3 and/or epigenetic drugs (5-Aza, TSA) on m-R-27b expression. Melanoma cells were treated with 1,25(OH)2D3 (10−8 M), 5-Aza (10 μM), and TSA (15 ng/ml) alone or in combination with 1,25(OH)2D3. RT-PCR assessed miR-27b and compared to vehicle-treated control, after 24 h of treatment. Experiments were performed in duplicate and repeated at least twice. Error bars represent the SD, *p≤0.05.

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Western blot of VDR protein expression in 1,25(OH)2D3-responsive as compared to 1,25(OH)2D3-resistant melanoma cell lines. Nucleolin used as loading control, MCF7 breast cancer cells used as positive control. Representative images of three experiments are shown.

Figure 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4.

miR-125b expression after transfection of IGR cells with miScript miR-125b inhibitor. Endogenous miR-125b level was quantified by RT-PCR.

The treatment with 1,25(OH)2D3 alone or in combination with 5-Aza or TSA significantly decreased the miR-27b expression in 3 out of the 4 melanoma cell lines (Figure 2c).

Effect of expression level of VDR. As shown by western blot in (Figure 3) VDR protein levels were nearly the same in the 1,25(OH)2D3-responsive cells and the 1,25(OH)2D3-resistant cell lines. Thus, there was no correlation between VDR protein level and 1,25(OH)2D3-sensitivity in these melanoma cell lines.

Among the malignant melanoma cell lines, the IGR cells (1,25(OH)2D3-resistant) had a relatively high miR-125b expression level, which was associated with low VDR mRNA expression. For this reason, the effect of miR-125b antisense was assessed in this cell line. The VDR protein band was not easily detected by western blot, therefore both VDR monoclonal and VDR polyclonal antibodies were used to confirm the data (9, 12). RT-PCR analysis detected a significant decrease in the miR-125b level after transfection (Figure 4). Downstream analysis by RT-PCR to investigate whether the VDR mRNA was affected by the miR-125b inhibition and by western blot to analyze the VDR protein level provided evidence that miR-125b does not regulate transcriptional or post-transcriptional VDR gene expression in the IGR melanoma cell line (Figure 5, 6).

Discussion

It is well known that 1,25(OH)2D3 plays a potential role in the prevention and treatment of hyper-proliferative malignancies (13). Additionally, the antiproliferative effect of HDAC inhibitors and 1,25(OH)2D3 converge on the interaction of the un-liganded VDR with co-repressors recruiting multi-protein complexes containing HDACs and on the stimulation of cyclin-dependent kinase inhibitor (CDKI) genes (14). Moreover, the HDAC inhibitor TSA induces the CDKIs p18 and p19, whereas the CDKIs p21 and p27 are stimulated by 1,25(OH)2D3. In agreement with these findings, we previously reported additive antiproliferative effects of 1,25(OH)2D3 and TSA in 1,25(OH)2D3-resistant cell lines (3, 13).

Figure 5.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 5.

VDR mRNA expression level in IGR cells 24 h after transfection with miR-12b antisense Relative expression level: ratio between the target gene (VDR) and the corresponding housekeeping gene (HPRT). Experiments were performed in duplicate and repeated twice. Error bars represent the SD.

Figure 6.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 6.

Effect of transfection with miR-125b antisense on VDR protein expression in IGR cells. Western blot analysis using VDR polyclonal or monoclonal antibodies. Nucleolin used as loading control. Experiments were repeated three times and representative images are shown.

To date, more than 50 genes have been identified to be aberrantly hypermethylated during some phases of melanoma progression and metastasis (1, 5), and treatment with demethylating agents resulted in the re-expression of VDR transcripts in breast cancer cellss, which in turn re-established sensitivity to calcitriol (1, 15). These data may, at least in part, explain the additive antiproliferative effect of 1,25(OH)2D3 in combination with 5-Aza that associated with increase in the VDR mRNA after treating the melanoma cells with this combination.

Additionally, the transcriptional regulation of miRs expression has recently been examined in tumors with epigenetic modification of DNA via methylation or HDAC, and the induction or inhibition of miRs could be achieved by the inhibition of DNA methylation or HDAC (5, 16, 17). Few studies have analyzed the role of microRNA in the development and progression of melanoma. 86% of melanoma cell lines have been reported to have an alteration in their genomic loci containing miRNA genes (18, 19). Specifically, miR-27b and miR-125b are two out of approximately 76 listed miRNAs that have repeatedly been shown to become deregulated with tumor development and progression in general and in melanoma in particular (8, 18, 20).

In the present study, a strong reduction of miR-125b and miR-27b levels we observed after treatment with 1,25(OH)2D3 in combination with 5-Aza, which in turn was associated with VDR mRNA induction. Based on these results, we hypothesize that vitamin D signalling is abrogated by an epigenetic mechanism and that hypermethylation is of importance for VDR mRNA, miR-125b and miR-27b regulation. Moreover, the VDR protein level did not correlate with 1,25(OH)2D3-sensitivity in these melanoma cell lines. Furthermore, transfection with miR-125b antisense did not regulate the VDR gene expression at the transcriptional or the translational level. It is well known that the use of miRNA inhibitors to investigate the effect of endogenously expressed miRNAs can be challenging, as the VDR gene is regulated by more than one miRNA (18, 19). Thus the miR-125b may not be specific enough it might be necessary to inhibit more than one miRNA in melanoma cells to see an effect on VDR gene expression. Additionally, the NHM did not show a specific expression level of miR-125b or miR-27b that could help in differentiating between benign skin cells and malignant cells. Further studies will focus on determining more specific VDR miRNAs and investigating their effect on VDR expression and thus on 1,25(OH)2D3-responsiveness in malignant melanoma cell lines.

Acknowledgements

This work was supported in part by Syrian Government from the Ministry of Higher Education. We thank Nathaniel Saidu for his help in editing this manuscript.

  • Received September 19, 2011.
  • Revision received November 28, 2011.
  • Accepted November 28, 2011.
  • Copyright© 2012 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

References

  1. ↵
    1. Gallagher WM,
    2. Bergin OE,
    3. Rafferty M,
    4. Kelly ZD,
    5. Nolan IM,
    6. Fox EJ,
    7. Culhane AC,
    8. McArdle L,
    9. Fraga MF,
    10. Hughes L,
    11. Currid CA,
    12. O'Mahony F,
    13. Byrne A,
    14. Murphy AA,
    15. Moss C,
    16. McDonnell S,
    17. Stallings RL,
    18. Plumb JA,
    19. Esteller M,
    20. Brown R,
    21. Dervan PA,
    22. Easty DJ
    : Multiple markers for melanoma progression regulated by DNA methylation: insights from transcriptomic studies. Carcinogenesis 26: 1856-1867, 2005.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Plum LA,
    2. DeLuca HF
    : Vitamin D, disease and therapeutic opportunities. Nat Rev Drug Discov 9: 941-955, 2010.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Essa S,
    2. Denzer N,
    3. Mahlknecht U,
    4. Klein R,
    5. Collnot EM,
    6. Tilgen W,
    7. Reichrath J
    : VDR microRNA expression and epigenetic silencing of vitamin D signaling in melanoma cells. J Steroid Biochem Mol Biol 121: 110-113, 2010.
    OpenUrlCrossRefPubMed
    1. Gommersall LM,
    2. Khanim FL,
    3. Peehl DM,
    4. Doherty AH,
    5. Campbell MJ
    : Epigenetic repression of transcription by the Vitamin D3 receptor in prostate cancer cells. J Steroid Biochem Mol Biol 89-90: 251-256, 2004.
    OpenUrlPubMed
  4. ↵
    1. Howell PM J,
    2. Liu S,
    3. Ren S,
    4. Behlen C,
    5. Fodstad O,
    6. Riker AI
    : Epigenetics in human melanoma. Cancer Control 16: 200-218, 2009.
    OpenUrlPubMed
  5. ↵
    1. Essa S,
    2. Denzer N,
    3. Mahlknecht U
    : Klein R, Collnot EM and Reichrath J: Challenge and promise: the role of miRNA for pathogenesis and progression of malignant melanoma. Clin Epigenet 1: 7-11, 2010.
    OpenUrl
  6. ↵
    1. Guil S,
    2. Esteller M
    : DNA methylomes, histone codes and miRNAs: tying it all together. Int J Biochem Cell Biol 41: 87-95, 2009.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Pan YZ,
    2. Gao W,
    3. Yu AM
    : MicroRNAs regulate CYP3A4 expression via direct and indirect targeting. Drug Metab Dispos 37: 2112-2117, 2009.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Mohri T,
    2. Nakajima M,
    3. Takagi S,
    4. Komagata S,
    5. Yokoi T
    : MicroRNA regulates human vitamin D receptor. Int J Cancer 125: 1328-1333, 2009.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Buras RR,
    2. Schumaker LM,
    3. Davoodi F,
    4. Brenner RV,
    5. Shabahang M,
    6. Nauta RJ,
    7. Evans SR
    : Vitamin D receptors in breast cancer cells. Breast Cancer Res Treat 31: 191-202, 1994.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Gotz C,
    2. Bachmann C,
    3. Montenarh M
    : Inhibition of protein kinase CK2 leads to a modulation of androgen receptor dependent transcription in prostate cancer cells. Prostate 67: 125-134, 2007.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Wang Y,
    2. Becklund BR,
    3. DeLuca HF
    : Identification of a highly specific and versatile vitamin D receptor antibody. Arch Biochem Biophys 494: 166-177, 2010.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Carlberg C,
    2. Seuter S
    : A genomic perspective on vitamin D signaling. Anticancer Res 29: 3485-3493, 2009.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Malinen M,
    2. Saramaki A,
    3. Ropponen A,
    4. Degenhardt T,
    5. Vaisanen S,
    6. Carlberg C
    : Distinct HDACs regulate the transcriptional response of human cyclin-dependent kinase inhibitor genes to Trichostatin A and 1alpha,25-dihydroxyvitamin D3. Nucleic Acids Res 36: 121-132, 2008.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Marik R,
    2. Fackler M,
    3. Gabrielson E,
    4. Zeiger MA,
    5. Sukumar S,
    6. Stearns V,
    7. Umbircht CB
    . DNA methylation-related vitamin D receptor insensitivity in breast cancer. Cancer Biol Ther 10: 44-53, 2010.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Zhang S,
    2. Cai X,
    3. Huang F,
    4. Zhong W,
    5. Yu Z
    : Effect of trichostatin A on viability and microRNA expression in human pancreatic cancer cell line BxPC-3. Exp Oncol 30: 265-268, 2008.
    OpenUrlPubMed
  16. ↵
    1. Saito Y,
    2. Liang G,
    3. Egger G,
    4. Friedman JM,
    5. Chuang JC,
    6. Coetzee GA,
    7. Jones PA
    : Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 9: 435-443, 2006.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Philippiduo D,
    2. Schmitt M,
    3. Moser D,
    4. Margue Ch,
    5. Nazarov P. V,
    6. Muller A,
    7. Vallar L,
    8. Nashan D,
    9. Behrmann I,
    10. Kreis S
    : Signature of MicroRNAs and Selected MicroRNA Target Genes in Human Melanoma. American Association for Cancer Research 70: 4163, 2010.
    OpenUrl
  18. ↵
    1. Zhang L,
    2. Huang J,
    3. Yang N,
    4. Greshock J,
    5. Megraw MS,
    6. Giannakakis A,
    7. Liang S,
    8. Naylor TL,
    9. Barchetti A,
    10. Ward MR,
    11. Yao G,
    12. Medina A,
    13. O'Brien-Jenkins A,
    14. Katsaros D,
    15. Hatzigeorgiou A,
    16. Gimotty PA,
    17. Weber BL,
    18. Coukos G
    : MicroRNAs exhibit high frequency genomic alterations in human cancer. Proc. Natl Acad Sci USA 103(24): 9136-9141, 2006.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Mueller DW,
    2. Rehli M,
    3. Bosserhoff AK
    : miRNA expression profiling in melanocytes and melanoma cell lines reveals miRNAs associated with formation and progression of malignant melanoma. J Invest Dermatology 129: 1740-1751, 2009.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Anticancer Research: 32 (1)
Anticancer Research
Vol. 32, Issue 1
January 2012
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Signature of VDR miRNAs and Epigenetic Modulation of Vitamin D Signaling in Melanoma Cell Lines
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
7 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Signature of VDR miRNAs and Epigenetic Modulation of Vitamin D Signaling in Melanoma Cell Lines
SALMA ESSA, SANDRA REICHRATH, ULRICH MAHLKNECHT, MATHIAS MONTENARH, THOMAS VOGT, JÖRG REICHRATH
Anticancer Research Jan 2012, 32 (1) 383-389;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Signature of VDR miRNAs and Epigenetic Modulation of Vitamin D Signaling in Melanoma Cell Lines
SALMA ESSA, SANDRA REICHRATH, ULRICH MAHLKNECHT, MATHIAS MONTENARH, THOMAS VOGT, JÖRG REICHRATH
Anticancer Research Jan 2012, 32 (1) 383-389;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgements
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Association of Vitamin D Receptor Gene Polymorphisms With Melanoma Risk: A Meta-analysis and Systematic Review
  • BsmI (rs1544410) and FokI (rs2228570) vitamin D receptor polymorphisms, smoking, and body mass index as risk factors of cutaneous malignant melanoma in northeast Italy
  • Immunohistochemical evaluation of vitamin D receptor (VDR) expression in cutaneous melanoma tissues and four VDR gene polymorphisms
  • MicroRNA and Cancer Chemoprevention
  • Google Scholar

More in this TOC Section

  • The Difference between 14-Epi-previtamin D3 and 14-Epi-19-norprevitamin D3: Their Synthesis and Binding Affinity for Human VDR
  • The Scots' Paradox: Can Sun Exposure, or Lack of it, Explain Major Paradoxes in Epidemiology?
  • Optimal Serum Calcidiol Concentration for Cancer Prevention
Show more Proceedings of the 4th International Symposium on Vitamin D and Analogs in Cancer Prevention and Therapy, May 20-21, 2011, Homburg/Saar, Germany

Similar Articles

Anticancer Research

© 2023 Anticancer Research

Powered by HighWire